|
Post by bigchungus91354 on Apr 3, 2019 12:16:25 GMT -5
Bigchungus, a few days ago you accused MC of either being incompetent or a crook. Today you're thinking about buying more stock. You're confusing me. Edit:Here is part of what you said "Either 1.) Our CEO lacks the business sense of a 6th grade Junior Achievement member or 2.) he is providing share price depression for friends on the other side. Either way, its not good for shareholders." I think MNKD has a great and potentially revolutionary product. There have been some very obvious mistakes by the leadership, to the point that I am questioning whether they should be removed. This is how investing works, if you have a great product that is being foiled by poor leadership, you make your concerns know to the controlling authority and vote your shares accordingly. I'm in the same boat with Mike K, the product has great potential and can lift the company to financial success, but our leadership is dropping the ball (intentionally or not) and needs to go, or at least have some further separation of power that will prevent him from putting his and his cronies interests above those of the shareholders.
|
|
|
Post by #NoMoreNeedles on Apr 3, 2019 13:14:51 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!"
|
|
|
Post by wsulylecoug on Apr 3, 2019 13:39:55 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" If that's a true assessment, then those shares will stay in MNKD's pocket for awhile. The next question is...where does our next shot of cash come from???
|
|
|
Post by mannmade on Apr 3, 2019 13:45:26 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" If that's a true assessment, then those shares will stay in MNKD's pocket for awhile. The next question is...where does our next shot of cash come from??? Take your pick: 1. 2nd UTHR milestone: $12.5 2. 2nd UTHR molecule: $30m 3. RLS: Milestone: $? 4. Another outside molecule partner: $? 5. Increasing Afrezza revenue 6. $1.60 warrants: $40m 7. Uthr buyin or other partnership: $? 8. Dilution Am not speculating on any of the above here. Just trying to answer your question as best I can w options I know of.
|
|
|
Post by #NoMoreNeedles on Apr 3, 2019 13:58:56 GMT -5
Rob a bank (aka shareholders)
|
|
|
Post by tingtongtung on Apr 3, 2019 14:01:10 GMT -5
Sorry, it's been a while since I looked into the cash situation.
* How much cash do they (MNKD) have now? * What's the monthly burn rate?
I thought MNKD wants the warrants to be executed to get money for running business?
|
|
|
Post by barnstormer on Apr 3, 2019 14:14:05 GMT -5
The warrants might provide a stock ceiling, but they’re irrelevant to what ails MannKind, which is Afrezza sales. What’s being suggested is a trade, and not an investment. As an investment, buy when MannKind figures out what to do with Afrezza, or when there’s something new in the Technosphere pipeline. Well said. Afrezza isn't taking the market by storm as we all hoped. The current marketing plan isn't effective especially when at the cost of TV, a sales force that is underwhelming and a top heavy management team that lacks the know how to fight BP. If sales were ahead of last years high of 700 scrips, the market would notice and the share price would respond. We should have had BIOMM and Cipla approved by now. Two global victories no matter how small would shake things up. Mikes's white wash of the Cipla approval failure is a prime example. If you want to win in the market place you have to be completely involved in the process. His admission that he only found out about it when the rest of the world did is astonishing. The fact that he says "This doesn't impact our timeline for regulatory approval in Brazil or India, but can't give a best case/worst case estimate or a read out on what efforts are being taken to move the process forward is BS. If investors had any level of confidence he was out in front of global expansion they might be able to contend with the anemic domestic sales better and the share price would be above the pitifully low warrants excersise price
|
|
|
Post by sellhighdrinklow on Apr 3, 2019 14:23:07 GMT -5
Or, Mannkind and MC want the 2.38 warrants to expire because there is bigger news pending that will move the stock up substantially and they can do an offering at the substantially higher price. Just a thought. Fingers crossed
|
|
|
Post by cretin11 on Apr 3, 2019 14:28:58 GMT -5
Confirmation from Mike: "Hoping [warrants] expire so we don't have dilution!" Was this a social media post from MC?
|
|
|
Post by mannmade on Apr 3, 2019 15:03:43 GMT -5
Or, Mannkind and MC want the 2.38 warrants to expire because there is bigger news pending that will move the stock up substantially and they can do an offering at the substantially higher price. Just a thought. Fingers crossed and what about the $1.6 warrants at end of the year?
|
|
|
Post by sportsrancho on Apr 3, 2019 15:10:29 GMT -5
|
|
|
Post by sportsrancho on Apr 3, 2019 15:11:21 GMT -5
|
|
|
Post by patten1962 on Apr 3, 2019 15:28:41 GMT -5
Or, Mannkind and MC want the 2.38 warrants to expire because there is bigger news pending that will move the stock up substantially and they can do an offering at the substantially higher price. Just a thought. Fingers crossed and what about the $1.6 warrants at end of the year? Now that I understand! Great thought!
|
|
|
Post by wsulylecoug on Apr 3, 2019 15:33:23 GMT -5
If that's a true assessment, then those shares will stay in MNKD's pocket for awhile. The next question is...where does our next shot of cash come from??? Take your pick: 1. 2nd UTHR milestone: $12.5 2. 2nd UTHR molecule: $30m 3. RLS: Milestone: $? 4. Another outside molecule partner: $? 5. Increasing Afrezza revenue 6. $1.60 warrants: $40m 7. Uthr buyin or other partnership: $? 8. Dilution Am not speculating on any of the above here. Just trying to answer your question as best I can w options I know of. Pulling together some of the responses from above, I'm in the same boat as TTT, I haven't dug into cash on hand, burn rate, payments due, Afrezza sales, and DF requirement to know how far we can get with what we've got. That's on me...but the general feeling of our current situation is that we need to check off a couple more of your items to comfortably get into 2020...and hopefully the ever elusive hockey stick. Adding 9. "because there is bigger news pending that will move the stock up substantially and they can do an offering at the substantially higher price. Just a thought. Fingers crossed" Depending upon the outlook, short-term vs long-term, #'s 1 & 6 seem likely to occur, with 6 getting an asterisk for being ~10% drop in PPS from going away. #8 might happen, but certainly hoping not unless 9 kicks in. All the rest are "hopes" as well...and man am I hoping one or two or three or......hit just like the original UTHR agreement. I guess you could say that some of the above is speculation on my part. I do like the long list of possibilities but would like a little less mystery, which probably means whole lot more of #5 instead of one-timers like many of the others. I'll wait and add bits and pieces here and there when the piggy bank allows.
|
|
|
Post by tingtongtung on Apr 3, 2019 16:13:49 GMT -5
Take your pick: 1. 2nd UTHR milestone: $12.5 2. 2nd UTHR molecule: $30m 3. RLS: Milestone: $? 4. Another outside molecule partner: $? 5. Increasing Afrezza revenue 6. $1.60 warrants: $40m 7. Uthr buyin or other partnership: $? 8. Dilution Am not speculating on any of the above here. Just trying to answer your question as best I can w options I know of. ...... Adding 9. "because there is bigger news pending that will move the stock up substantially and they can do an offering at the substantially higher price. Just a thought. Fingers crossed"
..... Honestly speaking, what could be that bigger news? A partnership/some investment from some company? After being an investor :-( here for a *long* time, I'm not so sure. They are not showing the growth in scripts that's needed to get other companies excited. I know the revenue has increased by ~2x times. But, the scripts has not (I know the units have been changed, etc). Other than UTHR everything has not been good so far. Don't get me wrong. I believe in Afrezza, but the way MNKD management is handling it is bad. Eventually being that good, Afrezza will be in SOC. But, if you get a 2x-3x return on your investment after 30 years (I think I bought my first lot in 2005/6), what good is that? The opportunity cost will drown that 2x-3x returns. It's good for the patients, but not for the investors. They have done almost everything (cleaning up the debts, getting rid of short term ones, renegotiating with AMPH, Deerfield is gone(?), etc). Now anything they do in terms of debts, etc. will be diminishing returns. They have to do only 2 things: 1. Raise money to do business. 2. Grow scripts (have to work with insurance) If they do (2) well, (1) will be taken care of. Since, (2) is not going really well, (1) is in spotlight. I'm too lazy to find the current cash in hand, and the burn rate (last I remember it was ~25million/qtr). The UTHR milestone payment is just peanuts unless they have money for at least 2 qtrs. Sorry - just my opinion. I don't understand their game plan at all. They could have just picked CA and CT states, and let all their sales people target the patients/doctors in these 2 states. I'm sure you will easily get more than 1000 patients from these 2 states. Once you establish yourself, then target other states, and then the world. But they have no money, but still want to target the whole US and the world. Come on! And, they should have realized by now ( 5 years after the approval) that insurance is the main issue here. I'm not sure what they are doing to mitigate that. We haven't heard any concrete plans/what has been achieved so far from them. I'm not a short. I have been long for almost 15 years. I just sold some for a big loss in Feb. I will sell some more for another big loss shortly. I just can't lock-up cash for years. May be I will buy back by ASM (after the wash sale stuff). Even after these 2 sells, I will still have close to 6 digit shares. This has been a horrible investment for me, but I believe in Afrezza and Dr. Mann. Hopefully, we get something back from MNKD :-)
|
|